Curis, Inc. received written notice from the Nasdaq Stock Market LLC on July 24, 2026, confirming that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the Bid Price Rule). The company is now in full compliance with the terms set forth by the Nasdaq Hearings Panel. Consequently, Curis will be subject to a Discretionary Panel Monitor for a one-year period starting July 24, 2026. During this monitor period, the company cannot submit a plan of compliance for new deficiencies, and staff cannot grant additional time to regain compliance if requirements are breached. Failure to maintain compliance may result in a delist determination letter and a subsequent hearing. Curis operates in the biotechnology industry, focusing on the development of cancer therapies.
